Ratings Biogen Inc. Xetra

Equities

IDP

US09062X1037

Market Closed - Xetra Other stock markets 16:35:35 22/05/2024 BST			After market 17:41:01
207.2 ^EUR	-0.91%		207.8	+0.31%

06:33pm	Top Midday Stories: US Targets August 1 Start Date for China Tariff Hikes; CFPB Says BNPL Requires Credit Card-Level Oversight; Target Shares Fall on Earnings Miss; Third BHP Bid Rejected by Anglo American	MT
03:58pm	Wedbush Raises Biogen Price Target to $219 From $215, Maintains Neutral Rating	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
With an enterprise value anticipated at 3.8 times the sales for the current fiscal year, the company turns out to be overvalued.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past four months, analysts' average price target has been revised downwards significantly.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
BIOGEN INC.	-11.75%	33.15B	-
CSL LIMITED	-2.99%	89.49B	A-
SAMSUNG BIOLOGICS CO.,LTD.	+2.24%	40.67B	A-
UCB	+61.72%	26.45B	A
BIOMARIN PHARMACEUTICAL INC.	-20.07%	14.69B	C
INCYTE CORPORATION	-7.68%	12.89B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.64%	11.54B	D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.34B	B
SWEDISH ORPHAN BIOVITRUM AB	+4.27%	8.84B	B+
INNOVENT BIOLOGICS, INC.	-11.11%	7.96B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes